Brand Name
Itvisma
Generic Name
Onasemnogene Abeparvovec-brve
View Brand Information FDA approval date: November 24, 2025
Form: Injection
What is Itvisma (Onasemnogene Abeparvovec-brve)?
ITVISMA is indicated for the treatment of spinal muscular atrophy in adult and pediatric patients 2 years of age and older with confirmed mutation in survival motor neuron 1 gene. ITVISMA is an adeno-associated virus vector-based gene therapy indicated for the treatment of spinal muscular atrophy in adult and pediatric patients 2 years of age and older with confirmed mutation in SMN1 gene.
Approved To Treat
Top Global Experts
There are no experts for this drug
Save this treatment for later
Not sure about your diagnosis?
Related Clinical Trials
There is no clinical trials being done for this treatment
Related Latest Advances
There is no latest advances for this treatment